

Mini review: Stress and how it affects reproduction

Author(s): Amar Chatterjee, Mohd Hamim Rajikin, Rita Chatterjee, Sumitabha Ghosh

Vol. 17, No. 1 (2006-01 - 2006-04)

Biomedical Research 2006; 17 (1): 1-6

Amar Chatterjee, Mohd Hamim Rajikin, Rita Chatterjee, Sumitabha Ghosh*

Department of Physiology, Faculty of Medicine, Universiti Teknologi MARA, 40450 Shah Alam, Selangor, Malaysia
,gnihcuK 05139 ,kawaraS aisyalam itisrevinU ,secneicS htlaeH & enicideM fo ytlucaF* Sarawak, Malaysia

Accepted December 09, 2005

Abstract

Chronic anxiety, depression or physical exertion-associated stress consistently activates the hypothalamic-pituitary-adrenal (HPA) axis. Each individual component of the HPA axis, such as CRH, ACTH, β -endorphin or glucocorticoid exerts deleterious effect on the hypo-thalamic-pituitary-gonadal (HPG) axis and subsequently leads to reproductive failure. Gonadotropin-releasing hormone (GnRH) secretion and the response of gonadotrophs to GnRH stimulation are severely impaired. Moreover, failure of gonadal response to gonad-otropin concurrently results in deficient steroidogenesis, anovulation, defective endometrial decidualization and implantation, abnormal fetal outcome and delayed parturition.

In male, a consistent testosterone deficiency due to stress-linked altered functioning of the HPG axis has also been documented.

Stress-associated growth hormone (GH) deficiency with a corresponding deficiency of insulin-like growth factor-1 (IGF-1) at the level of the hypothalamus, pituitary, ovary, and uter-ine endometrium leads to defective reproductive outcome and lactation.

GH or IGF-1 deficiency also impairs testosterone biosynthesis, spermatogenesis, sperm maturation and erectile process.

Introduction

Activation of the HPA axis concurrently inhibits HPG axis in stress

Individuals frequently encounter stressful conditions. In vertebrates, a major mechanism of physiological response to stress is hyperactivation of the hypothalamic-pituitary-

adrenal (HPA) axis. HPA axis hyperactivation is evident in major depressive [1,2] and anxiety [3] disorders. The occurrence of persistent increase in serum concentration of glucocorticoid in physical and psychological stress in primates [4,5], rodents [6] and domestic species [7] is well documented.

Chronic hyperactivation of glucocorticoids, however, re-sults in the development of diabetes, hypertension and even cancer [8]. The principal regulator of the HPA axis, corticotrophin-releasing hormone (CRH) and its receptors are located in the ovaries, decidual endometrial stroma, placental trophoblast and even in the Leydig cells of the testis [9-12].

Although the inhibitory effect of CRH in decreased LH and FSH secretion [13], ovarian steroidogenesis [14] and testosterone biosynthesis [15] has been documented, yet the locally produced CRH is found to be essential in promoting endometrial decidualization and implantation [16]. CRH may moreover act as the placental clock to trigger the onset of parturition [17]. On the other hand, CRH-activated β -endorphin [18] or corticotropin (ACTH) [19] is known to suppress the gonadotropin-releasing hormone (GnRH) pulses [18,20] with a corresponding attenuation of pulsatile release of luteinizing hormone (LH) [21,22] which subsequently leads to anovulation [23], interruption of endometrial decidualization [24] and pregnancy wastage [25].

The essential rhythmic pattern of GnRH secretion from the hypothalamus leads to an increased pulsatile release of LH [26]. Moreover, in concert with follicle stimulating hormone (FSH), LH dictates preovulatory follicular growth and estrogen production which subsequently trig-gers LH surge and ovulation [27]. Daley et al [28] have shown that stress-like concentration of glucocorticoid blocks estrogen-dependent increase in pituitary tissue concentration of GnRH and GnRH receptor mRNA. Therefore, the concept of glucocorticoid-linked reduced responsiveness of the gonadotrophs to GnRH [29] with a corresponding attenuation of gonadotropin secretion [30] seems to be logical. An excess of glucocorticoid has been found to suppress GnRH secretion [31].

Experimental results of the effectiveness of excessive glucocorticoid on gonadotropin secretion, however, re-main conflicting. When animal studies have linked increased CRH to decreased gonadotropin secretion [32], human studies using short-term infusion of CRH [33], conversely presented contradictory data. Since glucocorti-coid receptors have been demonstrated in rat ovaries [34] and ovarian granulosa cell cytosol [35], the direct effect of glucocorticoids [34] could possibly result in follicular atresia [36] by suppressing the action of LH/hCG at the receptor level [37]. Glucocorticoid-induced suppression of granulosa cell aromatase enzyme activity finally re-sults in estrogen deficiency [38]. Estrogen deficiency has also been recorded in anxiety and depression-related stress [39].

Investigators have recorded that glucocorticoid could greatly diminish the tissue uptake of estrogen [40] and estrogen-stimulated synthesis of DNA in the uterus [41]. Moreover, the number of estrogen receptors [42], blood flow [43], protein synthesis [44], prostaglandin synthesis [45] and insulin-like growth factor-1 (IGF-1) mRNA ex-pression

[46] in the uterus are found to be inhibited by glucocorticoids. Most of these estrogen-induced uterine profiles are essentially important for blastocyst implantation [47], endometrial decidualization [48], pregnancy maintenance [49] and parturition [50]. It is, however, important to note that glucocorticoid receptors in the uterus remain unaltered under the condition of chronic stress or even after prolonged glucocorticoid administration [51]. Estrogen deficiency not only impairs luteal steroidogenesis in pregnant rats [52], it also jeopardizes receptor expression of estrogen and progesterone in uteri [53], which subsequently results in pregnancy wastage [54] and parturition failure [50]. Moreover, the parental stress-associated shorter gestation, complicated delivery, smaller birth weight in humans [55,56] could possibly be linked to the free access of excess glucocorticoid through placental barrier [57]. Excess glucocorticoid is also found to cause delayed parturition and still birth in rats [50]. Highly anxious women have similarly been shown to have a significant reduction of uterine blood flow in the third trimester of pregnancy, as compared to less anxious women [58]. In rats, chronic stress during pregnancy exerts profound long-term influences on the offspring [59].

Although females are known to be more vulnerable to stress and exhibits hyperactivity of the HPA axis function in comparison to male animals [60,61], yet the site of chronic stress-associated lesion of the hypothalamic-pituitary-testicular axis has been identified to be at the level of the hypothalamus [62]. Exogenous glucocorticoid is also found to attenuate plasma testosterone concentration in men by inhibiting GnRH secretion [29,63]. The suppressive effect of ACTH on gonadotropin secretion [64] has been recorded in male patients with Cushing's syndrome [65]. Moreover, the suppressive effect of ACTH on gonadotropin secretion has never been recorded in patients with adrenocortical insufficiency [66].

Glucocorticoid receptors have been located in the rat Leydig cells [67]. The restraint stress-induced reduction in plasma concentration of testosterone, however, is claimed to be LH-independent [68], but appears to be related to the inhibition of the activities of steroidogenic enzymes [69]. β -endorphin blocker, such as naloxone or naltrexone has been shown to counteract the inhibitory effect of restraint stress on plasma testosterone levels by maintaining the normal functioning of the testicular steroidogenic enzymes [70]. In stressed rats, a concomitant rise in testicular nitric oxide (NO) concurrently with down regulated testosterone production has also been documented [71].

HPA axis activation and suppression of the GH-IGF-1 axis

The HPA axis activation and growth hormone (GH) blunting have in fact been linked in a primate study [72]. A blunted GH response to clonidine has however, been experienced in both anxiety and depression [73]. Attenuated release of GH in response to stress has been recognized long ago in experimental animals [74]. Experimental evidences suggest that GH may function as a gonadotropin [75]. GH receptor mRNA expression and GH binding protein (GHBP) have been detected in the ovary of humans [76] and in several animal species [77-79]. A number of in vitro studies have shown that GH can influence oocyte maturation, increase receptors to gonadotropin, thereby aiding folliculogenesis [80].

It is known that sexual maturation is delayed in Laron dwarfism [81] and growth hormone insensitivity also impairs the ability of young adult female mice to form functional corpora lutea of pregnancy [82]. However, a full

Stress and reproduction

reproductive potential requires actions of GH and adequate levels of insulin-like growth factor-1 (IGF-1) in peripheral circulation [83]. Therefore, to induce ovulation in Laron dwarfism, IGF-1 treatment is often preferred [84]. GH-receptor gene knockout mice are found to be IGF-1 deficient [85]. IGF-1 receptors were detected in the pituitary, gonads and reproductive tract [86] and the influence of IGF-1 on the release of GnRH [87] and gonadotropin [83], follicular steroidogenesis, ovarian follicular growth, and ovulation [see 88] have also been documented.

IGF-1 mRNA was identified in the adult testis [89]. In the human testis, IGF-1 was also identified in Leydig cells, Sertoli cells and primary spermatocytes [90]. A vital role of IGF-1 in testicular steroidogenesis [91] has also been suggested. GH treatment to adult GH/IGF-1-deficient Ames dwarf mice increased plasma IGF-1 level and concurrently increased androstenedione and testosterone release from the isolated testes [92]. In hypophysectomized rats, GH administration resulted in an increase in the LH receptor content of the testis [93] and GH has been shown to enhance the testicular responsiveness to gonadotropin treatment [94].

Although, an enormous amount of experimental and clinical data are available, the absolute pathway between the stress-induced hyperactivation of the HPA axis and corresponding attenuation of the HPG axis has yet to be determined

Acknowledgement

The encouraging cooperation of Dato' Professor Khalid Yusoff (Dean) and Dato' Professor Khairul Anuar Abdul-lah (Deputy Dean, Academic), Faculty of Medicine, Universiti Teknologi MARA, is highly appreciated.

References

1. Bjorntorp P. Behavior and metabolic disease. *Int J Behav Med* 1996; 3: 285-302.
2. Chrousos GP, Gold PW. The concept of stress and stress system disorders. Overview of physical and behavioral homeostasis. *JAMA* 1992; 267: 1244-1252.
3. Chrousos GP et al. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. *Ann Intern Med* 1998; 129: 229-240.
4. Darrell WB et al. Corticosteroid regulation of gonadotropin and prolactin secretion in the rat. *Endocrinology* 1990; 126: 159-166.
5. Norman RL et al. Restraint inhibits luteinizing hormone secretion in the follicular phase of the menstrual cycle in rhesus macaques. *Biol Reprod* 1994; 50: 16-26.

6. Suzuki S et al. Pituitary-dependent and independent secretion of CS caused by bacterial endotoxin in rats. *Am J Physiol* 1986; 250: E470-E 474.
7. Guillaume V et al. Effect of chronic active immunization anti-corticotropin-releasing factor on the pituitary-adrenal function in the sheep. *Endocrinology* 1992; 130: 2291-2298.
8. McEwen BS. Stress adaptation and disease. Allostasis and allostatic load. *N Y Acad Sci* 1998; 840: 33-44.
9. Mastorakos et al Immunoreactive corticotrophin-releasing hormone and its binding Sites in the rat ovary. *J Clin Invest* 1993; 92: 961-968.
10. Mastorakos G et al. Presence of immunoreactive corticotrophin-releasing hormone in human endometrium. *J Clin Endocrinol Metab* 1996; 81: 1046-1050.
11. Petraglia F et al. Human decidua and in vitro decidualized endometrial stromal cells at term contain immunoreactive corticotropin-releasing factor (CRF) and CRF-messenger ribonucleic acid. *J Clin Endocrinol Metab* 1992; 74: 1427-1431.
12. Makrigiannakis A et al. Corticotropin-releasing hormone (CRH) is expressed at the implantation sites of early pregnant rat uterus. *Life Sci* 1995; 57: 1869-1875.
13. Deborah HO, Michel F. Corticotropin-releasing hormone inhibits gonadotropin secretion in the ovariectomized rhesus monkey. *J Clin Endocrinol Metab* 1987; 65: 262-267.
14. Ghizzoni L et al. Corticotropin-releasing hormone (CRH) inhibits steroid biosynthesis by cultured human granulosa lutein cells in a CRH and interleukin-1 receptor mediated fashion. *Endocrinology* 1997; 130: 4806-4811.
15. Fabri A et al. Corticotropin-releasing factor is produced by the rat Leydig cells and has a major local antireproductive role in the testis. *Endocrinology* 1990; 127: 1541-1543.
16. Zoumakis E et al. Cycle and age related changes in corticotrophin-releasing hormone Level in human endometrium and ovaries. *Gynecol Endocrinol* 2001; 15: 98-102.
17. Challis JRG et al. Endocrine and paracrine regulation of birth at term and preterm. *Endocr Rev* 2000; 21: 514 -550.
18. Chen MD et al. Hypothalamic “stress” and gonadotro-pin-releasing pulse generator activity in the rhesus monkey: role of the ovary. *Neuroendocrinology* 1992; 56: 666-673.
19. Plotsky PM. Pathways to the secretion of adrenocorti-cotropin- a view from the portal. *J Neuroendocrinol* 1991; 3: 1-9.
20. Morley JE. The endocrinology of the opiate and opioid peptides. *Metabolism* 1981; 30: 195-209.
21. Schulz R et al. β -endorphin and dynorphine control serum luteinizing hormone level in Immature female rats. *Nature* 1981; 294: 757.
22. Kinoshita F et al. Effect of β -endorphin on pulsatile luteinizing hormone release in conscious castrated rats. *Life Sci* 1980; 27: 843-848.
23. Chatterjee A et al. Acute physical activity and its impact on ovulation in rats. *Biomed Res* 1994; 5: 57-60.
24. Chatterjee A et al. Treadmill running modulates endo-metrial decidualization in rats. *Biomed Res* 1995; 6: 109-113.

25. Chatterjee A, Harper MJK. Interruption of implantation and gestation in rats by reserpine, chlorpromazine and ACTH: possible mode of action. *Endocrinology* 1970; 87: 966-969.
26. Moenter SM et al. The estradiol-induced surge of gonadotropin-releasing hormone in the ewe. *Endocrinology* 1990; 127: 1375-1384.
27. McNeilly AS et al. Gonadotrophic control of follicle growth in the ewe. *J Reprod Fertil* 1991; 92: 177-186.
28. Daley CA et al. Effect of stress-like concentration of cortisol on the feedback potency of estradiol in orchid-dectomized sheep. *Anim Reprod Sci* 2000; 59: 167-178.
29. Sakakura N et al. Inhibition of luteinizing hormone secretion induced by synthetic LRH By long-term treatment with glucocorticoids in human subjects. *J Clin Endocrinol Metab* 1975; 40: 774-779.
30. Fonda et al. The effect of adrenocorticotropin or hydrocortisone on serum luteinizing hormone concentrations after adrenalectomy and/or ovariectomy in the prepubertal girls. *Endocrinology* 1984; 114: 268-273.
31. Dubey AK, Plant TM. A suppression of gonadotropin secretion by cortisol in castrated rhesus monkeys (*Macaca mulatta*) mediated by the interruption of hypothalamic gonadotropin-releasing hormone. *Biol Reprod* 1985; 33: 423-431.
32. Olster DH, Ferin M. Corticotropin-releasing hormone inhibits gonadotropin secretion in the ovariectomized rhesus monkey. *J Clin Endocrinol Metab* 1987; 65: 262-267.
33. Thomas MA et al. Dose-response effects of exogenous pulsatile human corticotrophin-releasing hormone on adrenocorticotropin, cortisol and gonadotropin concentrations in agonadal women. *J Clin Endocrinol Metab* 1991; 72: 1249-1254.
34. Shreiber JR et al. Rat ovary glucocorticoid receptor: identification and characterization. *Steroids* 1982; 39: 569-584.
35. Louvet JP et al. Glucocorticoid receptors in rat ovarian granulosa cell cytosol. 59th Annual Meeting of The Endocrine Society, Chicago IL, 1977; p 601 (Abstract).
36. Meurer KA et al. Decreased follicular steroids and insulin-like growth factor-1 and increased atresia in diabetic gilts during follicular growth stimulated with PMSG. *J Reprod Fert* 1991; 91: 187-196.
37. Schoonmaker JN, Erickson GF. Glucocorticoid modulation of follicle-stimulating hormone-mediated granulosa cell differentiation. *Endocrinology* 1983; 1356-1363.
38. Hsueh AJW, Erickson GF. Glucocorticoid inhibition of FSH-mediated estrogen production of cultured rat granulosa cells. *Steroids* 1983; 32: 639-643.
39. Andrade TG et al. Anxiolytic effect of estradiol in the median raphe nucleus mediated by 5-HT_{1A} receptors. *Behav Brain Res* 2005; 163: 18-25.
40. Campbell PS. The mechanism of the inhibition of uterotrophic responses by acute dexamethasone pretreatment. *Endocrinology* 1978; 103: 716-723.
41. Bigsby RM. Progesterone and dexamethasone inhibition of estrogen-induced synthesis of DNA and complement in rat uterine epithelium: effects of anti-progesterone compounds. *J Steroid Biochem Mol Biol* 1993; 45: 295-301.

42. Zamorano P et al. Effects of 5 alpha-dihydrotestosterone and dexamethasone on estrogen receptors of the anterior pituitary and uterus. *Steroids* 1992; 57: 18-26.
43. Monheit AG, Resnik R. Corticoid suppression of estrogen-induced uterine blood flow in nonpregnant sheep. *Am J Obstet Gynecol* 1981; 139: 454-458.
44. Sullivan DA et al. Steroid hormone regulation of free secretory component in the rat uterus. *Immunology* 1983; 49: 379-386.
45. Jacobs AL et al. Regulated expression of prostaglandin endoperoxide synthase-2 by uterine stroma. *Endocrinology* 1994; 135: 1807-1815.
46. Sahlin L. Dexamethasone attenuates the estradiol-induced increase of IGF-1 mRNA in the rat uterus. *J Steroid Biochem Mol Biol* 1995; 55: 9-15.
47. Psychoyos A. Endocrine control of egg implantation. In: Greep RO, Astwood EG, Greiger SR (eds.) *Hand Book of Physiology Vol II, part 2*. American Physiological Society, Washington DC 1973; 187-215.
48. Chatterjee et al. Dexamethasone modulation of endometrial decidualization in rats. *Biomed Res* 1995; 6: 153-156.
49. Chatterjee A. The possible mode of action of prostaglandins: VII. Evidence of antifertility effect of prostaglandin E1 in rats. *Prostaglandins* 1974; 6: 413-416.
50. Chatterjee A et al. Dexamethasone modulation of gestation length and parturition in rats. *Pharmacol Res* 1993; 27: 359-364.
51. Gunin AG. Effect of long-term glucocorticoid treatment on estradiol-induced proliferation in the uterus of ovariectomized rats. *J Endocrinol* 1998; 157: 481-488.
52. Shetty et al. Blockade of estrogen synthesis with an aromatase inhibitor affects luteal function of the pseudopregnant rat. *J Steroid Biochem Mol Biol* 1995; 55: 347-353.
53. Bergman et al. Upregulation of uterine oestrogen receptor and its messenger ribonucleic acid during the mouse oestrous cycle: The role of oestradiol. *Endocrinology* 1992; 130: 1923-1930.
54. Sulaiman SA et al. Indigenous herbal formulation and its contraceptive profile in rats. *Biomed Res* 2001; 12: 65-69.
55. Hedegaard M et al. Do stressful life events affect duration of gestation and risk of preterm delivery? *Epidemiology* 1996; 7: 339-345.
56. da Costa D et al. Psychological predictors of labor/ delivery and infant birth weight: a prospective multivariate study. *J Psychosom Obstet Gynecol* 2000; 21: 137-148.
57. Gitau R et al. Fetal exposure to maternal cortisol. *The Lancet* 1998; 352: 707-708.
58. Teixeira JM et al. Association between maternal anxiety in pregnancy and increased uterine artery resistance index: cohort based study. *BMJ* 1999; 318: 153-157.
59. Maccari S et al. Prenatal stress and long-term consequences: implications of glucocorticoid hormones. *Neurosci Biobehav Rev* 2003; 27: 119-127.
60. Kennett GA et al. Female rats are more vulnerable than males in an animal model of depression: the possible role of serotonin. *Brain Res* 1986; 382: 416-421.
61. Weinstock M et al. Gender differences in sympathoadrenal activity in rats at rest and in response to footshock stress. *Int J Dev Neurosci* 1998; 16: 289-295.

62. Lopez-Calderon A et al. Stress-induced changes in testis function. *J Steroid Biochem Mol Biol* 1991; 40: 473 -479.
63. Vierhapper H. LH-RH stimulated LH secretion in human endocrine disease. *Acta Endocrinol* 1985; 109: 1- 25.
64. Vierhapper H et al. Suppression of luteinizing hormone induced by adrenocorticotropin in healthy women. *J Endocrinol* 1981; 91: 399-403.
65. Luton J-P et al. Reversible gonadotropin deficiency in male Cushing's disease. *J Clin Endocrinol Metab* 1977; 45: 488-495.
66. Vierhapper H et al. Gonadotropin secretion in adreno-cortical insufficiency: Impact of glucocorticoid substitution. *Acta Endocrinol* 1982; 101: 580-585.
67. Stalker A et al. Covalent affinity labeling radioautography, and immunocytochemistry localized the glucocorticoid receptor in rat testicular Leydig cells. *Am J Anat* 1989; 386: 369-377.
68. Orr TE, Mann DR. Effect of restraint stress on plasma LH and testosterone concentrations, Leydig cell LH/ hCG receptors, and in vitro testicular steroidogenesis in adult rats. *Horm Behav* 1990; 24: 324-341.
69. Hales DB, Payne AH. Glucocorticoid-mediated repression of P450_{scc} mRNA and de novo synthesis in cultured Leydig cells. *Endocrinology* 1989; 124: 2099-2104.
70. Kostic T et al. The effect of opioid antagonists in local regulation of testicular response to acute stress in adult rats. *Steroids* 1997; 62: 703-708.
71. Tatjana S et al. Inhibitory effects of stress-activated nitric oxide on antioxidant enzymes and testicular steroidogenesis. *J Steroid Biochem Mol Biol* 2000; 75: 299 -306.
72. Coplan et al. Growth hormone response to clonidine in adversely reared young adult primates: relationship to serial cerebrospinal fluid corticotropin-releasing factor concentrations. *Psychiatry Res* 2000; 95: 93-102.
73. Uhde TW et al. Blunted growth hormone response to clonidine in panic disorder patients. *Biol Psychiatry* 1986; 21: 1081-1085.
74. Campbell GA et al. Effects of starvation in rats on serum levels of follicle stimulating hormone, luteinizing hormone, thyrotropin, growth hormone and prolactin; response to LH-releasing hormone and thyrotropin-releasing hormone. *Endocrinology* 1977; 100: 580-587.
75. Childs GV et al. Cells that express luteinizing hormone (LH) and follicle-stimulating hormone (FSH) beta-subunit messenger ribonucleic acids during the estrous cycle: the major contributors contain LH beta, FSH beta and/or growth hormone. *Endocrinology* 1994; 134: 990-997.
76. Sharara FI, Nieman LK. Identification and cellular localization of growth hormone receptor gene expression in the human ovary. *J Clin Endocrinol Metab* 1994; 79: 670-672.
77. Lobie PE et al. Cellular localization of the growth hormone receptor/binding protein in the male and female reproductive systems. *Endocrinology* 1990; 126: 2214- 2221.
78. Yuan W, Lucy MC. Messenger ribonucleic acid expression for growth hormone receptor, luteinizing hormone receptor and steroidogenic enzymes during the

- estrous cycle and pregnancy in porcine and bovine corpora lutea. *Domest Anim Endocrinol* 1996; 13: 431-444.
79. Sakaguchi K et al. Tissue-specific regulation of growth hormone receptor and growth hormone binding protein gene expression during pregnancy and lactation in the rat. *Endocr J* 1998; 45: S105-107.
 80. Sirotkin AV, Makarevich AV. Growth hormone can regulate functions of porcine ovarian Granulosa cells through the cAMP/protein kinase A system. *Anim Reprod Sci* 2002; 70: 111-126.
 81. Laron Z. Growth hormone insensitivity (Laron syndrome). *Rev Endocr Metab Disord* 2002; 3: 347-355.
 82. Zaczek D et al. Impact of growth hormone resistance on female reproductive function. New insights from growth hormone receptor knockout mice. *Biol Reprod* 2002; 67: 1115-1124.
 83. Chandrashekar et al. Pituitary and testicular function in growth hormone receptor gene knockout mice. *Endocrinology* 1999; 140: 1082-1088.
 84. Ibrahim ZHZ et al. The use of biosynthetic human growth hormone to augment ovulation induction with buserelin acetate human menopausal gonadotrophin treatment in women with a poor ovarian response. *Fertil Steril* 1991; 55: 204-204.
 85. Chandrashekar et al. Testicular endocrine function in growth hormone receptor gene disrupted mice. *Endocrinology* 2001; 142: 3443-3450.
 86. Codner E, Cassorla F. Growth hormone and reproductive function. *Mol Cell Endocrinol* 2002; 186: 133-136.
 87. Lackey BR et al. The insulin-like growth factor (IGF) system and gonadotropin regulation: actions and interactions. *Cytokine Growth Factor Rev* 1999; 10: 201-217.
 88. Mazerbourg S et al. The insulin-like growth factor system: a key determinant role in the growth and selection of ovarian follicles. A comparative species study. *Reprod Domest Anim* 2003; 38: 247-258.
 89. Lin T et al. Regulation of insulin-like growth factor-1 messenger ribonucleic acid expression in Leydig cells. *Mol Cell Endocrinol* 1990; 73: 147-152.
 90. Vannelli BG et al. Insulin-like growth factor-1 (IGF-1) and IGF-1 Receptor in human testis: an immunohistochemical study. *Fertil Steril* 1988; 49: 666-669.
 91. Kasson BG, Hsueh AJ. Insulin-like growth factor-1 augments gonadotropin-stimulated androgen biosynthesis by cultured rat testicular cells. *Mol Cell Endocrinol* 1987; 52: 27-34.
 92. Chandrashekar V, Bartke A. Induction of endogenous insulin-like growth factor-1 secretion alters the hypothalamic-pituitary-testicular function in growth hormone deficient adult dwarf mice. *Biol Reprod* 1993; 48: 544-551.
 93. Zipf WB et al. Prolactin, growth hormone and luteinizing hormone in the maintenance of testicular luteinizing hormone receptor. *Endocrinology* 1978; 103: 595-600.
 94. Swerdloff RS, Odell WD. Modulating influence of FSH, GH and prolactin on LH-stimulated testosterone secretion. In: Troen P, Nankin HR (eds.), *The Testis in Normal and Infertile Men*. New York: Raven Press; 1977; 395-401.

Correspondence and reprint request:

Amar Chatterjee

Department of Physiology, Faculty of Medicine, Universiti Teknologi MARA

40450 Shah Alam, Selangor, Malaysia

e-mail: amar_chatterjee (at) hotmail.com